Clinical Trial Update: A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT) [Phase 3]

View source ↗

Summary

Phase 3 trial of intravesical apaziquone (Qapzola) as a surgical adjuvant during TURBT for bladder cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Qapzola (apaziquone)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Bladder Cancer | Phase 3 | Status: TERMINATED | Results posted: 2021-09-28